LuciSelin 20 mg Tablet

Description

Unlock new treatment possibilities with LuciSelin (Selinexor), a cutting-edge nuclear export inhibitor designed to enhance therapeutic outcomes for patients battling multiple myeloma. LuciSelin is specifically formulated to be used in combination with bortezomib and dexamethasone for adult patients who have undergone at least one prior therapy, providing a powerful approach to combat this challenging disease. For those facing relapsed or refractory multiple myeloma, LuciSelin offers a crucial option when paired with dexamethasone, targeting adult patients who have experienced at least four prior therapies and whose disease remains resistant to multiple treatment modalities, including two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Additionally, LuciSelin is effective for adult patients battling relapsed or refractory diffuse large B-cell lymphoma, representing a beacon of hope in their treatment journey. Choose LuciSelin (Selinexor) for a comprehensive and innovative approach to managing complex hematologic conditions.